Sep 16, 2020 / 06:40PM GMT
Alethia Rene Young - Cantor Fitzgerald & Co., Research Division - Head of Healthcare Research
Hey, everybody. It's Alethia Young here. I cover large cap, small mid cap biotech here at Cantor. Very happy to have Sarepta Therapeutics. It probably needs no introduction, but I will introduce them anyway. We've got our main man, Doug Ingram, here on the left square if you could see my box, President and CEO; and in the lower square, you've got the man of the hour, Ian Estepan, who's SVP, Chief of Staff and Corporate Affairs. You got to keep the intros lively at this hour, right?
Questions and Answers:
Alethia Rene Young - Cantor Fitzgerald & Co., Research Division - Head of Healthcare ResearchI want to just kind of start off, Doug, your gene therapy really needs no introduction, and we'll obviously we'll get into those in a fair amount. But I think one thing that's important to talk about is the breadth of the pipeline and the platform technologies. So talk about that and then just also talk about some of the upcoming catalysts and milestones over the
Trustpilot
